A consolidated shareholder derivative lawsuit against Abbott Laboratories has been filed in federal court, as a result of concerns over contamination at the company’s infant formula manufacturing facility in Michigan. This wide-ranging litigation, spanning 181 pages, was initiated by court-appointed lead plaintiffs, following the factory’s closure, which was deemed necessary after investigations by the Food and Drug Administration (FDA).
The Michigan-based plant, located in Sturgis, was closed by Abbott Laboratories on February 15, 2022. This move was swiftly followed by a voluntary recall of potentially tainted infant formula products issued by the company on February 17, 2022. According to the filed opinion, these inspective measures were instigated in response to multiple regulatory violations discovered during the FDA’s inspections, and distressing incidents of infant fatalities linked to consumption of the contaminated baby formula.
The lawsuit implicates not only Abbott Laboratories, but also the CEO, Robert B. Ford, as well as members of the company’s board of directors, and various other executives within the company. The precise allegations and legal ramifications this suit will entail remains an unfolding situation.
For more in-depth details, you can read the litigation document from the federal court proceedings.